

# Impact of COVID-19 Outbreak on Human Immumoglobulin (PH4) for Intravenous Injection, Global Market Research Report 2020

<https://marketpublishers.com/r/l699291171DFEN.html>

Date: June 2020

Pages: 94

Price: US\$ 2,900.00 (Single User License)

ID: I699291171DFEN

## Abstracts

This report also analyses the impact of Coronavirus COVID-19 on the Human Immumoglobulin (PH4) for Intravenous Injection industry.

Based on our recent survey, we have several different scenarios about the Human Immumoglobulin (PH4) for Intravenous Injection YoY growth rate for 2020. The probable scenario is expected to grow by a xx% in 2020 and the revenue will be xx in 2020 from US\$ xx million in 2019. The market size of Human Immumoglobulin (PH4) for Intravenous Injection will reach xx in 2026, with a CAGR of xx% from 2020 to 2026.

### Market Segment Analysis

The research report includes specific segments by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2015 to 2026. Understanding the segments helps in identifying the importance of different factors that aid the market growth.

Segment by Type, the Human Immumoglobulin (PH4) for Intravenous Injection market is segmented into

1g/20ml

1.25g/25ml

2.5g/50ml

5g/100ml

10g/200ml

### Segment by Application

Hospital

Clinic

Others

### Global Human Immumoglobulin (PH4) for Intravenous Injection Market: Regional Analysis

The Human Immumoglobulin (PH4) for Intravenous Injection market is analysed and market size information is provided by regions (countries). The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type and by Application segment in terms of sales and revenue for the period 2015-2026.

The key regions covered in the Human Immumoglobulin (PH4) for Intravenous Injection market report are:

North America

U.S.

Canada

Europe

Germany

France

U.K.

Italy

Russia

## Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Indonesia

Thailand

Malaysia

Philippines

Vietnam

## Latin America

Mexico

Brazil

Argentina

## Middle East & Africa

Turkey

Saudi Arabia

U.A.E

## Global Human Immumoglobulin (PH4) for Intravenous Injection Market: Competitive Analysis

This section of the report identifies various key manufacturers of the market. It helps the reader understand the strategies and collaborations that players are focusing on combat competition in the market. The comprehensive report provides a significant microscopic look at the market. The reader can identify the footprints of the manufacturers by knowing about the global revenue of manufacturers, the global price of manufacturers, and sales by manufacturers during the forecast period of 2015 to 2019.

The major players in global Human Immumoglobulin (PH4) for Intravenous Injection market include:

Boya-Bio

Beijing Tiantan Biological Products

Guangdong Shuagnlin Bio-pharmacy

Weiguang Biological

Hualan Bio

CTBB

Sinopharm

Nanyue Biopharming

Shanghai RAAS

## Contents

### **1 HUMAN IMMUMOGLOBULIN (PH4) FOR INTRAVENOUS INJECTION MARKET OVERVIEW**

1.1 Product Overview and Scope of Human Immumoglobulin (PH4) for Intravenous Injection

1.2 Covid-19 Implications on Human Immumoglobulin (PH4) for Intravenous Injection Segment by Type

1.2.1 Global Human Immumoglobulin (PH4) for Intravenous Injection Sales Growth Rate Comparison by Type (2021-2026)

1.2.2 1g/20ml

1.2.3 1.25g/25ml

1.2.4 2.5g/50ml

1.2.5 5g/100ml

1.2.6 10g/200ml

1.3 Covid-19 Implications on Human Immumoglobulin (PH4) for Intravenous Injection Segment by Application

1.3.1 Human Immumoglobulin (PH4) for Intravenous Injection Sales Comparison by Application: 2020 VS 2026

1.3.2 Hospital

1.3.3 Clinic

1.3.4 Others

1.4 Covid-19 Implications on Global Human Immumoglobulin (PH4) for Intravenous Injection Market Size Estimates and Forecasts

1.4.1 Global Human Immumoglobulin (PH4) for Intravenous Injection Revenue 2015-2026

1.4.2 Global Human Immumoglobulin (PH4) for Intravenous Injection Sales 2015-2026

1.4.3 Human Immumoglobulin (PH4) for Intravenous Injection Market Size by Region: 2020 Versus 2026

1.5 Coronavirus Disease 2019 (Covid-19): Human Immumoglobulin (PH4) for Intravenous Injection Industry Impact

1.5.1 How the Covid-19 is Affecting the Human Immumoglobulin (PH4) for Intravenous Injection Industry

1.5.1.1 Human Immumoglobulin (PH4) for Intravenous Injection Business Impact Assessment - Covid-19

1.5.1.2 Supply Chain Challenges

1.5.1.3 COVID-19's Impact On Crude Oil and Refined Products

1.5.2 Market Trends and Human Immumoglobulin (PH4) for Intravenous Injection

## Potential Opportunities in the COVID-19 Landscape

### 1.5.3 Measures / Proposal against Covid-19

#### 1.5.3.1 Government Measures to Combat Covid-19 Impact

#### 1.5.3.2 Proposal for Human Immumoglobulin (PH4) for Intravenous Injection Players to Combat Covid-19 Impact

## **2 COVID-19 IMPLICATIONS ON GLOBAL HUMAN IMMUMOGLOBULIN (PH4) FOR INTRAVENOUS INJECTION MARKET COMPETITION BY MANUFACTURERS**

### 2.1 Global Human Immumoglobulin (PH4) for Intravenous Injection Sales Market Share by Manufacturers (2015-2020)

### 2.2 Global Human Immumoglobulin (PH4) for Intravenous Injection Revenue Share by Manufacturers (2015-2020)

### 2.3 Global Human Immumoglobulin (PH4) for Intravenous Injection Average Price by Manufacturers (2015-2020)

### 2.4 Manufacturers Human Immumoglobulin (PH4) for Intravenous Injection Manufacturing Sites, Area Served, Product Type

### 2.5 Human Immumoglobulin (PH4) for Intravenous Injection Market Competitive Situation and Trends

#### 2.5.1 Human Immumoglobulin (PH4) for Intravenous Injection Market Concentration Rate

#### 2.5.2 Global Top 5 and Top 10 Players Market Share by Revenue

#### 2.5.3 Market Share by Company Type (Tier 1, Tier 2 and Tier 3)

### 2.6 Manufacturers Mergers & Acquisitions, Expansion Plans

### 2.7 Primary Interviews with Key Human Immumoglobulin (PH4) for Intravenous Injection Players (Opinion Leaders)

## **3 COVID-19 IMPLICATIONS ON HUMAN IMMUMOGLOBULIN (PH4) FOR INTRAVENOUS INJECTION RETROSPECTIVE MARKET SCENARIO BY REGION**

### 3.1 Global Human Immumoglobulin (PH4) for Intravenous Injection Retrospective Market Scenario in Sales by Region: 2015-2020

### 3.2 Global Human Immumoglobulin (PH4) for Intravenous Injection Retrospective Market Scenario in Revenue by Region: 2015-2020

### 3.3 North America Human Immumoglobulin (PH4) for Intravenous Injection Market Facts & Figures by Country

#### 3.3.1 North America Human Immumoglobulin (PH4) for Intravenous Injection Sales by Country

#### 3.3.2 North America Human Immumoglobulin (PH4) for Intravenous Injection Sales by

## Country

3.3.3 U.S.

3.3.4 Canada

## 3.4 Europe Human Immumoglobulin (PH4) for Intravenous Injection Market Facts & Figures by Country

3.4.1 Europe Human Immumoglobulin (PH4) for Intravenous Injection Sales by Country

3.4.2 Europe Human Immumoglobulin (PH4) for Intravenous Injection Sales by Country

3.4.3 Germany

3.4.4 France

3.4.5 U.K.

3.4.6 Italy

3.4.7 Russia

## 3.5 Asia Pacific Human Immumoglobulin (PH4) for Intravenous Injection Market Facts & Figures by Region

3.5.1 Asia Pacific Human Immumoglobulin (PH4) for Intravenous Injection Sales by Region

3.5.2 Asia Pacific Human Immumoglobulin (PH4) for Intravenous Injection Sales by Region

3.5.3 China

3.5.4 Japan

3.5.5 South Korea

3.5.6 India

3.5.7 Australia

3.5.8 Taiwan

3.5.9 Indonesia

3.5.10 Thailand

3.5.11 Malaysia

3.5.12 Philippines

3.5.13 Vietnam

## 3.6 Latin America Human Immumoglobulin (PH4) for Intravenous Injection Market Facts & Figures by Country

3.6.1 Latin America Human Immumoglobulin (PH4) for Intravenous Injection Sales by Country

3.6.2 Latin America Human Immumoglobulin (PH4) for Intravenous Injection Sales by Country

3.6.3 Mexico

3.6.3 Brazil

### 3.6.3 Argentina

## 3.7 Middle East and Africa Human Immumoglobulin (PH4) for Intravenous Injection Market Facts & Figures by Country

### 3.7.1 Middle East and Africa Human Immumoglobulin (PH4) for Intravenous Injection Sales by Country

### 3.7.2 Middle East and Africa Human Immumoglobulin (PH4) for Intravenous Injection Sales by Country

### 3.7.3 Turkey

### 3.7.4 Saudi Arabia

### 3.7.5 U.A.E

## **4 GLOBAL HUMAN IMMUMOGLOBULIN (PH4) FOR INTRAVENOUS INJECTION HISTORIC MARKET ANALYSIS BY TYPE**

### 4.1 Global Human Immumoglobulin (PH4) for Intravenous Injection Sales Market Share by Type (2015-2020)

### 4.2 Global Human Immumoglobulin (PH4) for Intravenous Injection Revenue Market Share by Type (2015-2020)

### 4.3 Global Human Immumoglobulin (PH4) for Intravenous Injection Price Market Share by Type (2015-2020)

### 4.4 Global Human Immumoglobulin (PH4) for Intravenous Injection Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End

## **5 GLOBAL HUMAN IMMUMOGLOBULIN (PH4) FOR INTRAVENOUS INJECTION HISTORIC MARKET ANALYSIS BY APPLICATION**

### 5.1 Global Human Immumoglobulin (PH4) for Intravenous Injection Sales Market Share by Application (2015-2020)

### 5.2 Global Human Immumoglobulin (PH4) for Intravenous Injection Revenue Market Share by Application (2015-2020)

### 5.3 Global Human Immumoglobulin (PH4) for Intravenous Injection Price by Application (2015-2020)

## **6 COMPANY PROFILES AND KEY FIGURES IN HUMAN IMMUMOGLOBULIN (PH4) FOR INTRAVENOUS INJECTION BUSINESS**

### 6.1 Boya-Bio

#### 6.1.1 Corporation Information

#### 6.1.2 Boya-Bio Description, Business Overview and Total Revenue



- 6.1.3 Boya-Bio Human Immumoglobulin (PH4) for Intravenous Injection Sales, Revenue and Gross Margin (2015-2020)
- 6.1.4 Boya-Bio Products Offered
- 6.1.5 Boya-Bio Recent Development
- 6.2 Beijing Tiantan Biological Products
  - 6.2.1 Beijing Tiantan Biological Products Corporation Information
  - 6.2.2 Beijing Tiantan Biological Products Description, Business Overview and Total Revenue
  - 6.2.3 Beijing Tiantan Biological Products Human Immumoglobulin (PH4) for Intravenous Injection Sales, Revenue and Gross Margin (2015-2020)
  - 6.2.4 Beijing Tiantan Biological Products Products Offered
  - 6.2.5 Beijing Tiantan Biological Products Recent Development
- 6.3 Guangdong Shuagnlin Bio-pharmacy
  - 6.3.1 Guangdong Shuagnlin Bio-pharmacy Corporation Information
  - 6.3.2 Guangdong Shuagnlin Bio-pharmacy Description, Business Overview and Total Revenue
  - 6.3.3 Guangdong Shuagnlin Bio-pharmacy Human Immumoglobulin (PH4) for Intravenous Injection Sales, Revenue and Gross Margin (2015-2020)
  - 6.3.4 Guangdong Shuagnlin Bio-pharmacy Products Offered
  - 6.3.5 Guangdong Shuagnlin Bio-pharmacy Recent Development
- 6.4 Weiguang Biological
  - 6.4.1 Weiguang Biological Corporation Information
  - 6.4.2 Weiguang Biological Description, Business Overview and Total Revenue
  - 6.4.3 Weiguang Biological Human Immumoglobulin (PH4) for Intravenous Injection Sales, Revenue and Gross Margin (2015-2020)
  - 6.4.4 Weiguang Biological Products Offered
  - 6.4.5 Weiguang Biological Recent Development
- 6.5 Hualan Bio
  - 6.5.1 Hualan Bio Corporation Information
  - 6.5.2 Hualan Bio Description, Business Overview and Total Revenue
  - 6.5.3 Hualan Bio Human Immumoglobulin (PH4) for Intravenous Injection Sales, Revenue and Gross Margin (2015-2020)
  - 6.5.4 Hualan Bio Products Offered
  - 6.5.5 Hualan Bio Recent Development
- 6.6 CTBB
  - 6.6.1 CTBB Corporation Information
  - 6.6.2 CTBB Description, Business Overview and Total Revenue
  - 6.6.3 CTBB Human Immumoglobulin (PH4) for Intravenous Injection Sales, Revenue and Gross Margin (2015-2020)

- 6.6.4 CTBB Products Offered
- 6.6.5 CTBB Recent Development
- 6.7 Sinopharm
  - 6.6.1 Sinopharm Corporation Information
  - 6.6.2 Sinopharm Description, Business Overview and Total Revenue
  - 6.6.3 Sinopharm Human Immumoglobulin (PH4) for Intravenous Injection Sales, Revenue and Gross Margin (2015-2020)
  - 6.4.4 Sinopharm Products Offered
  - 6.7.5 Sinopharm Recent Development
- 6.8 Nanyue Biopharming
  - 6.8.1 Nanyue Biopharming Corporation Information
  - 6.8.2 Nanyue Biopharming Description, Business Overview and Total Revenue
  - 6.8.3 Nanyue Biopharming Human Immumoglobulin (PH4) for Intravenous Injection Sales, Revenue and Gross Margin (2015-2020)
  - 6.8.4 Nanyue Biopharming Products Offered
  - 6.8.5 Nanyue Biopharming Recent Development
- 6.9 Shanghai RAAS
  - 6.9.1 Shanghai RAAS Corporation Information
  - 6.9.2 Shanghai RAAS Description, Business Overview and Total Revenue
  - 6.9.3 Shanghai RAAS Human Immumoglobulin (PH4) for Intravenous Injection Sales, Revenue and Gross Margin (2015-2020)
  - 6.9.4 Shanghai RAAS Products Offered
  - 6.9.5 Shanghai RAAS Recent Development

## **7 HUMAN IMMUMOGLOBULIN (PH4) FOR INTRAVENOUS INJECTION MANUFACTURING COST ANALYSIS**

- 7.1 Human Immumoglobulin (PH4) for Intravenous Injection Key Raw Materials Analysis
  - 7.1.1 Key Raw Materials
  - 7.1.2 Key Raw Materials Price Trend
  - 7.1.3 Key Suppliers of Raw Materials
- 7.2 Proportion of Manufacturing Cost Structure
- 7.3 Manufacturing Process Analysis of Human Immumoglobulin (PH4) for Intravenous Injection
- 7.4 Human Immumoglobulin (PH4) for Intravenous Injection Industrial Chain Analysis

## **8 MARKETING CHANNEL, DISTRIBUTORS AND CUSTOMERS**

- 8.1 Marketing Channel

8.2 Human Immumoglobulin (PH4) for Intravenous Injection Distributors List

8.3 Human Immumoglobulin (PH4) for Intravenous Injection Customers

## **9 MARKET DYNAMICS**

9.1 Market Trends

9.2 Opportunities and Drivers

9.3 Challenges

9.4 Porter's Five Forces Analysis

## **10 GLOBAL MARKET FORECAST**

10.1 Global Human Immumoglobulin (PH4) for Intravenous Injection Market Estimates and Projections by Type

10.1.1 Global Forecasted Sales of Human Immumoglobulin (PH4) for Intravenous Injection by Type (2021-2026)

10.1.2 Global Forecasted Revenue of Human Immumoglobulin (PH4) for Intravenous Injection by Type (2021-2026)

10.2 Human Immumoglobulin (PH4) for Intravenous Injection Market Estimates and Projections by Application

10.2.1 Global Forecasted Sales of Human Immumoglobulin (PH4) for Intravenous Injection by Application (2021-2026)

10.2.2 Global Forecasted Revenue of Human Immumoglobulin (PH4) for Intravenous Injection by Application (2021-2026)

10.3 Human Immumoglobulin (PH4) for Intravenous Injection Market Estimates and Projections by Region

10.3.1 Global Forecasted Sales of Human Immumoglobulin (PH4) for Intravenous Injection by Region (2021-2026)

10.3.2 Global Forecasted Revenue of Human Immumoglobulin (PH4) for Intravenous Injection by Region (2021-2026)

10.4 North America Human Immumoglobulin (PH4) for Intravenous Injection Estimates and Projections (2021-2026)

10.5 Europe Human Immumoglobulin (PH4) for Intravenous Injection Estimates and Projections (2021-2026)

10.6 Asia Pacific Human Immumoglobulin (PH4) for Intravenous Injection Estimates and Projections (2021-2026)

10.7 Latin America Human Immumoglobulin (PH4) for Intravenous Injection Estimates and Projections (2021-2026)

10.8 Middle East and Africa Human Immumoglobulin (PH4) for Intravenous Injection

Estimates and Projections (2021-2026)

## **11 RESEARCH FINDING AND CONCLUSION**

## **12 METHODOLOGY AND DATA SOURCE**

### 12.1 Methodology/Research Approach

#### 12.1.1 Research Programs/Design

#### 12.1.2 Market Size Estimation

#### 12.1.3 Market Breakdown and Data Triangulation

### 12.2 Data Source

#### 12.2.1 Secondary Sources

#### 12.2.2 Primary Sources

### 12.3 Author List

### 12.4 Disclaimer

## List Of Tables

### LIST OF TABLES

- Table 1. Global Human Immumoglobulin (PH4) for Intravenous Injection Sales (K Units) Growth Rate Comparison by Type (2015-2026)
- Table 2. Global Human Immumoglobulin (PH4) for Intravenous Injection Sales (K Units) Comparison by Application: 2020 VS 2026
- Table 3. Global Human Immumoglobulin (PH4) for Intravenous Injection Market Size by Type (K Units) (US\$ Million) (2020 VS 2026)
- Table 4. COVID-19 Impact Global Market: (Four Human Immumoglobulin (PH4) for Intravenous Injection Market Size Forecast Scenarios)
- Table 5. Opportunities and Trends for Human Immumoglobulin (PH4) for Intravenous Injection Players in the COVID-19 Landscape
- Table 6. Present Opportunities in China & Elsewhere Due to the Coronavirus Crisis
- Table 7. Key Regions/Countries Measures against Covid-19 Impact
- Table 8. Proposal for Human Immumoglobulin (PH4) for Intravenous Injection Players to Combat Covid-19 Impact
- Table 9. Global Key Human Immumoglobulin (PH4) for Intravenous Injection Manufacturers Covered in This Study
- Table 10. Global Human Immumoglobulin (PH4) for Intravenous Injection Sales (K Units) by Manufacturers (2015-2020)
- Table 11. Global Human Immumoglobulin (PH4) for Intravenous Injection Sales Share by Manufacturers (2015-2020)
- Table 12. Global Human Immumoglobulin (PH4) for Intravenous Injection Revenue (Million USD) by Manufacturers (2015-2020)
- Table 13. Global Human Immumoglobulin (PH4) for Intravenous Injection Revenue Share by Manufacturers (2015-2020)
- Table 14. Global Market Human Immumoglobulin (PH4) for Intravenous Injection Average Price (US\$/Unit) of Key Manufacturers (2015-2020)
- Table 15. Manufacturers Human Immumoglobulin (PH4) for Intravenous Injection Sales Sites and Area Served
- Table 16. Manufacturers Human Immumoglobulin (PH4) for Intravenous Injection Product Types
- Table 17. Global Human Immumoglobulin (PH4) for Intravenous Injection Manufacturers Market Concentration Ratio (CR5 and HHI)
- Table 18. Global Human Immumoglobulin (PH4) for Intravenous Injection by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Human Immumoglobulin (PH4) for Intravenous Injection as of 2019)

Table 19. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 20. Main Points Interviewed from Key Human Immumoglobulin (PH4) for Intravenous Injection Players

Table 21. Global Human Immumoglobulin (PH4) for Intravenous Injection Sales (K Units) by Region (2015-2020)

Table 22. Global Human Immumoglobulin (PH4) for Intravenous Injection Sales Market Share by Region (2015-2020)

Table 23. Global Human Immumoglobulin (PH4) for Intravenous Injection Revenue (Million US\$) by Region (2015-2020)

Table 24. Global Human Immumoglobulin (PH4) for Intravenous Injection Revenue Market Share by Region (2015-2020)

Table 25. North America Human Immumoglobulin (PH4) for Intravenous Injection Sales by Country (2015-2020) (K Units)

Table 26. North America Human Immumoglobulin (PH4) for Intravenous Injection Sales Market Share by Country (2015-2020)

Table 27. North America Human Immumoglobulin (PH4) for Intravenous Injection Revenue by Country (2015-2020) (US\$ Million)

Table 28. North America Human Immumoglobulin (PH4) for Intravenous Injection Revenue Market Share by Country (2015-2020)

Table 29. Europe Human Immumoglobulin (PH4) for Intravenous Injection Sales by Country (2015-2020) (K Units)

Table 30. Europe Human Immumoglobulin (PH4) for Intravenous Injection Sales Market Share by Country (2015-2020)

Table 31. Europe Human Immumoglobulin (PH4) for Intravenous Injection Revenue by Country (2015-2020) (US\$ Million)

Table 32. Europe Human Immumoglobulin (PH4) for Intravenous Injection Revenue Market Share by Country (2015-2020)

Table 33. Asia Pacific Human Immumoglobulin (PH4) for Intravenous Injection Sales by Region (2015-2020) (K Units)

Table 34. Asia Pacific Human Immumoglobulin (PH4) for Intravenous Injection Sales Market Share by Region (2015-2020)

Table 35. Asia Pacific Human Immumoglobulin (PH4) for Intravenous Injection Revenue by Region (2015-2020) (US\$ Million)

Table 36. Asia Pacific Human Immumoglobulin (PH4) for Intravenous Injection Revenue Market Share by Region (2015-2020)

Table 37. Latin America Human Immumoglobulin (PH4) for Intravenous Injection Sales by Country (2015-2020) (K Units)

Table 38. Latin America Human Immumoglobulin (PH4) for Intravenous Injection Sales Market Share by Country (2015-2020)

Table 39. Latin America Human Immumoglobulin (PH4) for Intravenous Injection Revenue by Country (2015-2020) (US\$ Million)

Table 40. Latin America Human Immumoglobulin (PH4) for Intravenous Injection Revenue Market Share by Country (2015-2020)

Table 41. Middle East and Africa Human Immumoglobulin (PH4) for Intravenous Injection Sales by Country (2015-2020) (K Units)

Table 42. Middle East and Africa Human Immumoglobulin (PH4) for Intravenous Injection Sales Market Share by Country (2015-2020)

Table 43. Middle East and Africa Human Immumoglobulin (PH4) for Intravenous Injection Revenue by Country (2015-2020) (US\$ Million)

Table 44. Middle East and Africa Human Immumoglobulin (PH4) for Intravenous Injection Revenue Market Share by Country (2015-2020)

Table 45. Global Human Immumoglobulin (PH4) for Intravenous Injection Sales (K Units) by Type (2015-2020)

Table 46. Global Human Immumoglobulin (PH4) for Intravenous Injection Sales Share by Type (2015-2020)

Table 47. Global Human Immumoglobulin (PH4) for Intravenous Injection Revenue (Million US\$) by Type (2015-2020)

Table 48. Global Human Immumoglobulin (PH4) for Intravenous Injection Revenue Share by Type (2015-2020)

Table 49. Global Human Immumoglobulin (PH4) for Intravenous Injection Price (US\$/Unit) by Type (2015-2020)

Table 50. Global Human Immumoglobulin (PH4) for Intravenous Injection Sales (K Units) by Application (2015-2020)

Table 51. Global Human Immumoglobulin (PH4) for Intravenous Injection Sales Market Share by Application (2015-2020)

Table 52. Global Human Immumoglobulin (PH4) for Intravenous Injection Sales Growth Rate by Application (2015-2020)

Table 53. Boya-Bio Human Immumoglobulin (PH4) for Intravenous Injection Corporation Information

Table 54. Boya-Bio Description and Business Overview

Table 55. Boya-Bio Human Immumoglobulin (PH4) for Intravenous Injection Sales (K Units), Revenue (Million US\$), Price (US\$/Unit) and Gross Margin (2015-2020)

Table 56. Boya-Bio Main Product

Table 57. Boya-Bio Recent Development

Table 58. Beijing Tiantan Biological Products Human Immumoglobulin (PH4) for Intravenous Injection Corporation Information

Table 59. Beijing Tiantan Biological Products Corporation Information

Table 60. Beijing Tiantan Biological Products Human Immumoglobulin (PH4) for

Intravenous Injection Sales (K Units), Revenue (Million US\$), Price (US\$/Unit) and Gross Margin (2015-2020)

Table 61. Beijing Tiantan Biological Products Main Product

Table 62. Beijing Tiantan Biological Products Recent Development

Table 63. Guangdong Shuagnlin Bio-pharmacy Human Immumoglobulin (PH4) for Intravenous Injection Corporation Information

Table 64. Guangdong Shuagnlin Bio-pharmacy Corporation Information

Table 65. Guangdong Shuagnlin Bio-pharmacy Human Immumoglobulin (PH4) for Intravenous Injection Sales (K Units), Revenue (Million US\$), Price (US\$/Unit) and Gross Margin (2015-2020)

Table 66. Guangdong Shuagnlin Bio-pharmacy Main Product

Table 67. Guangdong Shuagnlin Bio-pharmacy Recent Development

Table 68. Weiguang Biological Human Immumoglobulin (PH4) for Intravenous Injection Corporation Information

Table 69. Weiguang Biological Corporation Information

Table 70. Weiguang Biological Human Immumoglobulin (PH4) for Intravenous Injection Sales (K Units), Revenue (Million US\$), Price (US\$/Unit) and Gross Margin (2015-2020)

Table 71. Weiguang Biological Main Product

Table 72. Weiguang Biological Recent Development

Table 73. Hualan Bio Human Immumoglobulin (PH4) for Intravenous Injection Corporation Information

Table 74. Hualan Bio Corporation Information

Table 75. Hualan Bio Human Immumoglobulin (PH4) for Intravenous Injection Sales (K Units), Revenue (Million US\$), Price (US\$/Unit) and Gross Margin (2015-2020)

Table 76. Hualan Bio Main Product

Table 77. Hualan Bio Recent Development

Table 78. CTBB Human Immumoglobulin (PH4) for Intravenous Injection Corporation Information

Table 79. CTBB Corporation Information

Table 80. CTBB Human Immumoglobulin (PH4) for Intravenous Injection Sales (K Units), Revenue (Million US\$), Price (US\$/Unit) and Gross Margin (2015-2020)

Table 81. CTBB Main Product

Table 82. CTBB Recent Development

Table 83. Sinopharm Human Immumoglobulin (PH4) for Intravenous Injection Corporation Information

Table 84. Sinopharm Corporation Information

Table 85. Sinopharm Human Immumoglobulin (PH4) for Intravenous Injection Sales (K Units), Revenue (Million US\$), Price (US\$/Unit) and Gross Margin (2015-2020)

Table 86. Sinopharm Main Product



- Table 87. Sinopharm Recent Development
- Table 88. Nanyue Biopharming Human Immumoglobulin (PH4) for Intravenous Injection Corporation Information
- Table 89. Nanyue Biopharming Corporation Information
- Table 90. Nanyue Biopharming Human Immumoglobulin (PH4) for Intravenous Injection Sales (K Units), Revenue (Million US\$), Price (US\$/Unit) and Gross Margin (2015-2020)
- Table 91. Nanyue Biopharming Main Product
- Table 92. Nanyue Biopharming Recent Development
- Table 93. Shanghai RAAS Human Immumoglobulin (PH4) for Intravenous Injection Corporation Information
- Table 94. Shanghai RAAS Corporation Information
- Table 95. Shanghai RAAS Human Immumoglobulin (PH4) for Intravenous Injection Sales (K Units), Revenue (Million US\$), Price (US\$/Unit) and Gross Margin (2015-2020)
- Table 96. Shanghai RAAS Main Product
- Table 97. Shanghai RAAS Recent Development
- Table 98. Sales Base and Market Concentration Rate of Raw Material
- Table 99. Key Suppliers of Raw Materials
- Table 100. Human Immumoglobulin (PH4) for Intravenous Injection Distributors List
- Table 101. Human Immumoglobulin (PH4) for Intravenous Injection Customers List
- Table 102. Market Key Trends
- Table 103. Key Opportunities and Drivers: Impact Analysis (2021-2026)
- Table 104. Key Challenges
- Table 105. Global Human Immumoglobulin (PH4) for Intravenous Injection Sales (K Units) Forecast by Type (2021-2026)
- Table 106. Global Human Immumoglobulin (PH4) for Intravenous Injection Sales Market Share Forecast by Type (2021-2026)
- Table 107. Global Human Immumoglobulin (PH4) for Intravenous Injection Revenue (Million US\$) Forecast by Type (2021-2026)
- Table 108. Global Human Immumoglobulin (PH4) for Intravenous Injection Revenue (Million US\$) Market Share Forecast by Type (2021-2026)
- Table 109. Global Human Immumoglobulin (PH4) for Intravenous Injection Sales (K Units) Forecast by Application (2021-2026)
- Table 110. Global Human Immumoglobulin (PH4) for Intravenous Injection Revenue (Million US\$) Forecast by Application (2021-2026)
- Table 111. Global Human Immumoglobulin (PH4) for Intravenous Injection Sales (K Units) Forecast by Region (2021-2026)
- Table 112. Global Human Immumoglobulin (PH4) for Intravenous Injection Sales Market Share Forecast by Region (2021-2026)
- Table 113. Global Human Immumoglobulin (PH4) for Intravenous Injection Revenue

Forecast by Region (2021-2026) (US\$ Million)

Table 114. Global Human Immumoglobulin (PH4) for Intravenous Injection Revenue

Market Share Forecast by Region (2021-2026)

Table 115. Research Programs/Design for This Report

Table 116. Key Data Information from Secondary Sources

Table 117. Key Data Information from Primary Sources

## List Of Figures

### LIST OF FIGURES

- Figure 1. Picture of Human Immumoglobulin (PH4) for Intravenous Injection
- Figure 2. Global Human Immumoglobulin (PH4) for Intravenous Injection Sales Market Share by Type: 2020 VS 2026
- Figure 3. 1g/20ml Product Picture
- Figure 4. 1.25g/25ml Product Picture
- Figure 5. 2.5g/50ml Product Picture
- Figure 6. 5g/100ml Product Picture
- Figure 7. 10g/200ml Product Picture
- Figure 8. Global Human Immumoglobulin (PH4) for Intravenous Injection Consumption Market Share by Application: 2020 VS 2026
- Figure 9. Hospital
- Figure 10. Clinic
- Figure 11. Others
- Figure 12. Global Human Immumoglobulin (PH4) for Intravenous Injection Market Size 2015-2026 (US\$ Million)
- Figure 13. Global Human Immumoglobulin (PH4) for Intravenous Injection Sales Capacity (K Units) (2015-2026)
- Figure 14. Global Human Immumoglobulin (PH4) for Intravenous Injection Market Size Market Share by Region: 2020 Versus 2026
- Figure 15. Human Immumoglobulin (PH4) for Intravenous Injection Sales Share by Manufacturers in 2020
- Figure 16. Global Human Immumoglobulin (PH4) for Intravenous Injection Revenue Share by Manufacturers in 2019
- Figure 17. The Global 5 and 10 Largest Players: Market Share by Human Immumoglobulin (PH4) for Intravenous Injection Revenue in 2019
- Figure 18. Human Immumoglobulin (PH4) for Intravenous Injection Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
- Figure 19. Global Human Immumoglobulin (PH4) for Intravenous Injection Sales Market Share by Region (2015-2020)
- Figure 20. Global Human Immumoglobulin (PH4) for Intravenous Injection Sales Market Share by Region in 2019
- Figure 21. Global Human Immumoglobulin (PH4) for Intravenous Injection Revenue Market Share by Region (2015-2020)
- Figure 22. Global Human Immumoglobulin (PH4) for Intravenous Injection Revenue Market Share by Region in 2019

Figure 23. North America Human Immumoglobulin (PH4) for Intravenous Injection Sales Market Share by Country in 2019

Figure 24. North America Human Immumoglobulin (PH4) for Intravenous Injection Revenue Market Share by Country in 2019

Figure 25. U.S. Human Immumoglobulin (PH4) for Intravenous Injection Sales Growth Rate (2015-2020) (K Units)

Figure 26. U.S. Human Immumoglobulin (PH4) for Intravenous Injection Revenue Growth Rate (2015-2020) (US\$ Million)

Figure 27. Canada Human Immumoglobulin (PH4) for Intravenous Injection Sales Growth Rate (2015-2020) (K Units)

Figure 28. Canada Human Immumoglobulin (PH4) for Intravenous Injection Revenue Growth Rate (2015-2020) (US\$ Million)

Figure 29. Europe Human Immumoglobulin (PH4) for Intravenous Injection Sales Market Share by Country in 2019

Figure 30. Europe Human Immumoglobulin (PH4) for Intravenous Injection Revenue Market Share by Country in 2019

Figure 31. Germany Human Immumoglobulin (PH4) for Intravenous Injection Sales Growth Rate (2015-2020) (K Units)

Figure 32. Germany Human Immumoglobulin (PH4) for Intravenous Injection Revenue Growth Rate (2015-2020) (US\$ Million)

Figure 33. France Human Immumoglobulin (PH4) for Intravenous Injection Sales Growth Rate (2015-2020) (K Units)

Figure 34. France Human Immumoglobulin (PH4) for Intravenous Injection Revenue Growth Rate (2015-2020) (US\$ Million)

Figure 35. U.K. Human Immumoglobulin (PH4) for Intravenous Injection Sales Growth Rate (2015-2020) (K Units)

Figure 36. U.K. Human Immumoglobulin (PH4) for Intravenous Injection Revenue Growth Rate (2015-2020) (US\$ Million)

Figure 37. Italy Human Immumoglobulin (PH4) for Intravenous Injection Sales Growth Rate (2015-2020) (K Units)

Figure 38. Italy Human Immumoglobulin (PH4) for Intravenous Injection Revenue Growth Rate (2015-2020) (US\$ Million)

Figure 39. Russia Human Immumoglobulin (PH4) for Intravenous Injection Sales Growth Rate (2015-2020) (K Units)

Figure 40. Russia Human Immumoglobulin (PH4) for Intravenous Injection Revenue Growth Rate (2015-2020) (US\$ Million)

Figure 41. Asia Pacific Human Immumoglobulin (PH4) for Intravenous Injection Sales Market Share by Region in 2019

Figure 42. Asia Pacific Human Immumoglobulin (PH4) for Intravenous Injection

## Revenue Market Share by Region in 2019

Figure 43. China Human Immumoglobulin (PH4) for Intravenous Injection Sales Growth Rate (2015-2020) (K Units)

Figure 44. China Human Immumoglobulin (PH4) for Intravenous Injection Revenue Growth Rate (2015-2020) (US\$ Million)

Figure 45. Japan Human Immumoglobulin (PH4) for Intravenous Injection Sales Growth Rate (2015-2020) (K Units)

Figure 46. Japan Human Immumoglobulin (PH4) for Intravenous Injection Revenue Growth Rate (2015-2020) (US\$ Million)

Figure 47. South Korea Human Immumoglobulin (PH4) for Intravenous Injection Sales Growth Rate (2015-2020) (K Units)

Figure 48. South Korea Human Immumoglobulin (PH4) for Intravenous Injection Revenue Growth Rate (2015-2020) (US\$ Million)

Figure 49. India Human Immumoglobulin (PH4) for Intravenous Injection Sales Growth Rate (2015-2020) (K Units)

Figure 50. India Human Immumoglobulin (PH4) for Intravenous Injection Revenue Growth Rate (2015-2020) (US\$ Million)

Figure 51. Australia Human Immumoglobulin (PH4) for Intravenous Injection Sales Growth Rate (2015-2020) (K Units)

Figure 52. Australia Human Immumoglobulin (PH4) for Intravenous Injection Revenue Growth Rate (2015-2020) (US\$ Million)

Figure 53. Taiwan Human Immumoglobulin (PH4) for Intravenous Injection Sales Growth Rate (2015-2020) (K Units)

Figure 54. Taiwan Human Immumoglobulin (PH4) for Intravenous Injection Revenue Growth Rate (2015-2020) (US\$ Million)

Figure 55. Indonesia Human Immumoglobulin (PH4) for Intravenous Injection Sales Growth Rate (2015-2020) (K Units)

Figure 56. Indonesia Human Immumoglobulin (PH4) for Intravenous Injection Revenue Growth Rate (2015-2020) (US\$ Million)

Figure 57. Thailand Human Immumoglobulin (PH4) for Intravenous Injection Sales Growth Rate (2015-2020) (K Units)

Figure 58. Thailand Human Immumoglobulin (PH4) for Intravenous Injection Revenue Growth Rate (2015-2020) (US\$ Million)

Figure 59. Malaysia Human Immumoglobulin (PH4) for Intravenous Injection Sales Growth Rate (2015-2020) (K Units)

Figure 60. Malaysia Human Immumoglobulin (PH4) for Intravenous Injection Revenue Growth Rate (2015-2020) (US\$ Million)

Figure 61. Philippines Human Immumoglobulin (PH4) for Intravenous Injection Sales Growth Rate (2015-2020) (K Units)

Figure 62. Philippines Human Immumoglobulin (PH4) for Intravenous Injection Revenue Growth Rate (2015-2020) (US\$ Million)

Figure 63. Vietnam Human Immumoglobulin (PH4) for Intravenous Injection Sales Growth Rate (2015-2020) (K Units)

Figure 64. Vietnam Human Immumoglobulin (PH4) for Intravenous Injection Revenue Growth Rate (2015-2020) (US\$ Million)

Figure 65. Latin America Human Immumoglobulin (PH4) for Intravenous Injection Sales Market Share by Country in 2019

Figure 66. Latin America Human Immumoglobulin (PH4) for Intravenous Injection Revenue Market Share by Country in 2019

Figure 67. Mexico Human Immumoglobulin (PH4) for Intravenous Injection Sales Growth Rate (2015-2020) (K Units)

Figure 68. Mexico Human Immumoglobulin (PH4) for Intravenous Injection Revenue Growth Rate (2015-2020) (US\$ Million)

Figure 69. Brazil Human Immumoglobulin (PH4) for Intravenous Injection Sales Growth Rate (2015-2020) (K Units)

Figure 70. Brazil Human Immumoglobulin (PH4) for Intravenous Injection Revenue Growth Rate (2015-2020) (US\$ Million)

Figure 71. Argentina Human Immumoglobulin (PH4) for Intravenous Injection Sales Growth Rate (2015-2020) (K Units)

Figure 72. Argentina Human Immumoglobulin (PH4) for Intravenous Injection Revenue Growth Rate (2015-2020) (US\$ Million)

Figure 73. Middle East and Africa Human Immumoglobulin (PH4) for Intravenous Injection Sales Market Share by Country in 2019

Figure 74. Middle East and Africa Human Immumoglobulin (PH4) for Intravenous Injection Revenue Market Share by Country in 2019

Figure 75. Turkey Human Immumoglobulin (PH4) for Intravenous Injection Sales Growth Rate (2015-2020) (K Units)

Figure 76. Turkey Human Immumoglobulin (PH4) for Intravenous Injection Revenue Growth Rate (2015-2020) (US\$ Million)

Figure 77. Saudi Arabia Human Immumoglobulin (PH4) for Intravenous Injection Sales Growth Rate (2015-2020) (K Units)

Figure 78. Saudi Arabia Human Immumoglobulin (PH4) for Intravenous Injection Revenue Growth Rate (2015-2020) (US\$ Million)

Figure 79. U.A.E Human Immumoglobulin (PH4) for Intravenous Injection Sales Growth Rate (2015-2020) (K Units)

Figure 80. U.A.E Human Immumoglobulin (PH4) for Intravenous Injection Revenue Growth Rate (2015-2020) (US\$ Million)

Figure 81. Sales Market Share of Human Immumoglobulin (PH4) for Intravenous

Injection by Type (2015-2020)

Figure 82. Sales Market Share of Human Immumoglobulin (PH4) for Intravenous Injection by Type in 2019

Figure 83. Revenue Share of Human Immumoglobulin (PH4) for Intravenous Injection by Type (2015-2020)

Figure 84. Revenue Market Share of Human Immumoglobulin (PH4) for Intravenous Injection by Type in 2019

Figure 85. Global Human Immumoglobulin (PH4) for Intravenous Injection Sales Growth by Type (2015-2020) (K Units)

Figure 86. Global Human Immumoglobulin (PH4) for Intravenous Injection Sales Market Share by Application (2015-2020)

Figure 87. Global Human Immumoglobulin (PH4) for Intravenous Injection Sales Market Share by Application in 2019

Figure 88. Global Revenue Share of Human Immumoglobulin (PH4) for Intravenous Injection by Application (2015-2020)

Figure 89. Global Revenue Share of Human Immumoglobulin (PH4) for Intravenous Injection by Application in 2020

Figure 90. Boya-Bio Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 91. Beijing Tiantan Biological Products Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 92. Guangdong Shuagnlin Bio-pharmacy Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 93. Weiguang Biological Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 94. Hualan Bio Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 95. CTBB Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 96. Sinopharm Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 97. Nanyue Biopharming Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 98. Shanghai RAAS Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 99. Price Trend of Key Raw Materials

Figure 100. Manufacturing Cost Structure of Human Immumoglobulin (PH4) for Intravenous Injection

Figure 101. Manufacturing Process Analysis of Human Immumoglobulin (PH4) for Intravenous Injection

Figure 102. Human Immumoglobulin (PH4) for Intravenous Injection Industrial Chain Analysis

Figure 103. Channels of Distribution

Figure 104. Distributors Profiles

Figure 105. Porter's Five Forces Analysis

Figure 106. North America Human Immumoglobulin (PH4) for Intravenous Injection Sales (K Units) and Growth Rate Forecast (2021-2026)

Figure 107. North America Human Immumoglobulin (PH4) for Intravenous Injection Revenue (Million US\$) and Growth Rate Forecast (2021-2026)

Figure 108. Europe Human Immumoglobulin (PH4) for Intravenous Injection Sales (K Units) and Growth Rate Forecast (2021-2026)

Figure 109. Europe Human Immumoglobulin (PH4) for Intravenous Injection Revenue (Million US\$) and Growth Rate Forecast (2021-2026)

Figure 110. Latin America Human Immumoglobulin (PH4) for Intravenous Injection Sales (K Units) and Growth Rate Forecast (2021-2026)

Figure 111. Latin America Human Immumoglobulin (PH4) for Intravenous Injection Revenue (Million US\$) and Growth Rate Forecast (2021-2026)

Figure 112. Middle East and Africa Human Immumoglobulin (PH4) for Intravenous Injection Sales (K Units) and Growth Rate Forecast (2021-2026)

Figure 113. Middle East and Africa Human Immumoglobulin (PH4) for Intravenous Injection Revenue (Million US\$) and Growth Rate Forecast (2021-2026)

Figure 114. Asia Pacific Human Immumoglobulin (PH4) for Intravenous Injection Sales (K Units) and Growth Rate Forecast (2021-2026)

Figure 115. Asia Pacific Human Immumoglobulin (PH4) for Intravenous Injection Revenue (Million US\$) and Growth Rate Forecast (2021-2026)

Figure 116. Bottom-up and Top-down Approaches for This Report

Figure 117. Data Triangulation

Figure 118. Key Executives Interviewed



## I would like to order

Product name: Impact of COVID-19 Outbreak on Human Immumoglobulin (PH4) for Intravenous Injection, Global Market Research Report 2020

Product link: <https://marketpublishers.com/r/l699291171DFEN.html>

Price: US\$ 2,900.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/l699291171DFEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

